MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Tiludronate disodium

CAS No. : 149845-07-8

MCE 国际站：Tiludronate disodium

产品活性：Tiludronate (Tiludronic Acid) disodium 是一种口服活性双膦酸盐，可以起到骨调节作用。Tiludronate disodium 用于代谢性骨疾病的研究。Tiludronate disodium 是破骨细胞空泡H(+)-ATP酶的有效抑制剂。

研究领域：Membrane Transporter/Ion Channel

作用靶点：Proton Pump

In Vitro: The ability of Tiludronate to inhibit proton transport is 5-fold higher in kidney-derived vesicles (IC₅₀=1.1 mM) and 10,000-fold higher in vesicles derived from osteoclasts (IC₅₀=466 nM). Tiludronate also potently inhibits proton transport in yeast microsomal preparations (IC₅₀=3.5 microM) and inhibits the activity of purified yeast V-ATPase. The inhibition of the osteoclast V-ATPase-mediated proton transport by Tiludronate is rapid, pH-dependent, and reversible.

In Vivo: Tiludronate exerts a dose-dependent inhibitory activity on bone resorption. Tiludronate could act on mature osteoclasts by reducing their capacity to secrete proton into the resorption space and also by favoring their detachment from the bone matrix. Tiludronate is also tested in other models of osteoporosis. In the castrated male rat model, Tiludronate (5-200 mg/kg; p.o.) prevents the decrease in the skeletal mass, assessed physically by measuring the bone weight and density or chemically by determining the calcium and phosphate content.

相关产品：Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  Immunology/Inflammation Compound Library  |  Membrane Transporter/Ion Channel Compound Library  |  FDA-Approved Drug Library  |  Drug Repurposing Compound Library  |  Orally Active Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Drug-Induced Liver Injury (DILI) Compound Library  |  Human Metabolite Library  |  Off-patent Drug Library  |  Membrane Protein-targeted Compound Library  |  Membrane Receptor-targeted Compound Library  |  (R)-Lansoprazole  |  (R)-(+)-Pantoprazole-d₆  |  Esomeprazole-d₃  |  Omeprazole magnesium  |  Pantoprazole-d₃  |  Tegoprazan-d₆  |  PF 03716556  |  Omeprazole-d₃-1  |  CS-526  |  Rabeprazole-d₄  |  Esomeprazole sodium  |  Rabeprazole-d₄ sodium  |  SKF96067  |  Picoprazole  |  Abscisic acid-d₆  |  Pantoprazole-d₆  |  Pumaprazole  |  Bafilomycin A1  |  Vonoprazan Fumarate  |  Esomeprazole-d₃ sodium  |  5-Hydroxylansoprazole  |  Lansoprazole sulfone-d₄  |  Pantoprazole sodium  |  Revaprazan  |  (R)-Lansoprazole-d₄  |  Verucopeptin  |  Tiludronate disodium hemihydrate

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物  |  寡核苷酸  |  抗体  |  点击化学

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides  |  Antibodies  |  Click Chemistry

货号: HY-A0213A

品牌介绍:
•   MCE (MedChemExpress) 拥有200 多种全球独家化合物库，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；
•   50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领；
•   产品种类涵盖各种重组蛋白，多肽，常用试剂盒 ，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；
•   提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
•   专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。